Incontinence in late-onset pompe disease: An underdiagnosed treatable condition

European Neurology

Volumn 68, Issue 2, 2012, Pages 75-78

  Remiche, Gauthier ^a   Herbaut, Anne Geneviève ^a   Ronchi, Dario ^b   Lamperti, Costanza ^c   Magri, Francesca ^b   Moggio, Maurizio ^b   Bresolin, Nereo ^b   Comi, Giacomo P ^b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY OF MILAN   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN;

ANUS SPHINCTER; ASSISTED VENTILATION; BREATHING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EXAMINATION; CONSTIPATION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DYSAUTONOMIA; ELECTROMYOGRAM; ENZYME REPLACEMENT; FECES INCONTINENCE; FOLLOW UP; FORCED VITAL CAPACITY; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LETTER; LEVATOR ANI MUSCLE; LIMB WEAKNESS; MANOMETRY; MATERNAL WELFARE; MOBILIZATION; MOTONEURON; MUSCLE FUNCTION; MUSCLE STRENGTH; MYOTONIC DYSTROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PELVIS FLOOR; PELVIS SURGERY; PERIODIC ACID SCHIFF STAIN; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROSTATISM; QUALITY OF LIFE; RESPIRATORY FUNCTION; RISK FACTOR; SHORT FORM 36; URINE INCONTINENCE;

ADULT; AGE OF ONSET; AGED; COHORT STUDIES; ENZYME REPLACEMENT THERAPY; FECAL INCONTINENCE; FEMALE; GLUCAN 1,4-ALPHA-GLUCOSIDASE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; PREVALENCE; URINARY INCONTINENCE;

EID: 84863098528     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000338776     Document Type: Letter

References (31)

1. Kroos MA, Pomponio RJ, Hagemans ML, et al: Broad spectrum of Pompe disease in patients with the same c.-32-13t-1 g haplotype. Neurology 2007; 68: 110-115. (Pubitemid 46071893)
2. Raben N, Plotz P, Byrne BJ: Acid alpha-glucosidase deficiency (glycogenosis type ii, Pompe disease). Curr Mol Med 2002; 2: 145-166. (Pubitemid 34649837)
3. Engel A, Franzini-Armstrong C: Myology: Basic and Clinical, ed 3. New York, McGraw-Hill, Medical Pub. Division, 2004.
4. Engel AG, Gomez MR, Seybold ME, Lambert EH: The spectrum and diagnosis of acid maltase deficiency. Neurology 1973; 23: 95-106.
5. Van den Hout JM, Kamphoven JH, Winkel LP, et al: Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113:e448-e457.
6. Martiniuk F, Chen A, Mack A, et al: Carrier frequency for glycogen storage disease type ii in New York and estimates of affected individuals born with the disease. Am J Med Genet 1998; 79: 69-72. (Pubitemid 28402423)
7. Ausems MG, Verbiest J, Hermans MP, et al: Frequency of glycogen storage disease type ii in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999; 7: 713-716. (Pubitemid 29424063)
8. van der Ploeg AT, Reuser AJ: Pompe's disease. Lancet 2008; 372: 1342-1353.
9. Herbaut AG, Nogueira MC, Panzer JM, Zegers de Beyl D: Anorectal incontinence in myotonic dystrophy: a myopathic involvement of pelvic floor muscles. Muscle Nerve 1992; 15: 1210-1211.
10. Lecointe-Besancon I, Leroy F, Devroede G, et al: A comparative study of esophageal and anorectal motility in myotonic dystrophy. Dig Dis Sci 1999; 44: 1090-1099. (Pubitemid 29297210)
11. Abercrombie JF, Rogers J, Swash M: Faecal incontinence in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1998; 64: 128-130. (Pubitemid 28156552)
12. Sakakibara R, Hattori T, Tojo M, Yamanishi T, Yasuda K, Hirayama K: Micturitional disturbance in myotonic dystrophy. J Auton Nerv Syst 1995; 52: 17-21.
13. Caress JB, Kothari MJ, Bauer SB, Shefner JM: Urinary dysfunction in Duchenne muscular dystrophy. Muscle Nerve 1996; 19: 819-822. (Pubitemid 26190639)
14. MacLeod M, Kelly R, Robb SA, Borzyskowski M: Bladder dysfunction in Duchenne muscular dystrophy. Arch Dis Child 2003; 88: 347-349. (Pubitemid 36398980)
15. Miller TD, Jackson AP, Barresi R, et al: Inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD): clinical features including sphincter disturbance in a large pedigree. J Neurol Neurosurg Psychiatry 2009; 80: 583-584.
16. Alsheik EH, Coyne T, Hawes SK, et al: Fecal incontinence: prevalence, severity, and quality of life data from an outpatient gastroenterology practice. Gastroenterol Res Pract 2012; 2012: 947694.
17. Laforet P, Nicolino M, Eymard PB, et al: Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000; 55: 1122-1128.
18. Chancellor AM, Warlow CP, Webb JN, Lucas MG, Besley GT, Broadhead DM: Acid maltase deficiency presenting with a myopathy and exercise induced urinary incontinence in a 68 year old male. J Neurol Neurosurg Psychiatry 1991; 54: 659-660.
19. Bernstein DL, Bialer MG, Mehta L, Desnick RJ: Pompe disease: Dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab 2010; 101: 130-133.
20. Remiche G, Ronchi D, Lamperti C, et al: Adult form type ii glycogen storage disease in a northern Italy population: phenotype characterization, early diagnosis and prognostic determinants. Neurology 2008; 70:A309.
21. Hagemans ML, Janssens AC, Winkel LP, et al: Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 2004; 63: 1688-1692. (Pubitemid 39507589)
22. Whitehead WE, Borrud L, Goode PS, et al: Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology 2009; 137: 512-517, 517 e1-e2.
23. Markland AD, Richter HE, Fwu CW, Eggers P, Kusek JW: Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol 2011; 186: 589-593.
24. van der Ploeg AT, Clemens PR, Corzo D, et al: A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010; 362: 1396-1406.
25. Shotelersuk V, Shuangshoti S, Chotivitayatarakorn P, et al: Clinical, pathological, and electron microscopic findings in two Thai children with Pompe disease. J Med Assoc Thai 2002; 85(suppl 1):S271-S279.
26. Teng YT, Su WJ, Hou JW, Huang SF: Infantile-onset glycogen storage disease type ii (Pompe disease): report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 2004; 27: 379-384.
27. Thurberg BL, Lynch Maloney C, Vaccaro C, et al: Characterization of pre-and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006; 86: 1208-1220. (Pubitemid 44789911)
28. Bijvoet AG, Van Hirtum H, Vermey M, et al: Pathological features of glycogen storage disease type ii highlighted in the knockout mouse model. J Pathol 1999; 189: 416-424. (Pubitemid 29489228)
29. Sacconi S, Bocquet JD, Chanalet S, Tanant V, Salviati L, Desnuelle C: Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J Neurol 2010; 257: 1730-1733.
30. Laforet P, Petiot P, Nicolino M, et al: Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology 2008; 70: 2063-2066.
31. Winkel LP, Hagemans ML, van Doorn PA, et al: The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 2005; 252: 875-884. (Pubitemid 41186956)